-
Key mutations may cause cross-species transmission of new coronavirus
Time of Update: 2021-09-06
In the latest study, scientists from Virginia Tech analyzed 182,000 new coronavirus genomes to explore mutations that may help the virus adapt to and spread among humans .
-
Bristol-Myers Squibb BCMA CAR-T therapy Abecma receives EU CHMP support
Time of Update: 2021-09-06
CHMP adopted positive opinions based on the results of the pivotal Phase II KarMMa study, which evaluated the efficacy and safety of Abecma in 128 patients with severe pre-treatment and highly refractory multiple myeloma .
Bristol Myers Squibb Receives Positive CHMP Opinion for Anti-BCMA CAR T Cell Therapy Abecma (idecabtagene vicleucel) for Relapsed and Refractory Multiple Myeloma2.
-
Infection with the new coronavirus can change the size and hardness of blood cells or help explain why disease symptoms last longer
Time of Update: 2021-09-06
Science and Technology Daily News (Reporter Liu Xia) According to a recent report by the physicist organization network, German scientists discovered for the first time that the new coronavirus can significantly change the size and hardness of red blood cells and white blood cells in the human body using a real-time cell deformation measuring instrument.
-
New coronavirus infection and genetic factors of the disease are determined for the first time
Time of Update: 2021-09-06
A large-scale international collaborative research analysis identified the genetic factors of human neocoronavirus infection and neocorona pneumonia disease severity for the first time, and identified 13 new genomic regions related to susceptibility and disease severity .
-
Roche/Regeneron New Coronary Neutralizing Antibody Therapy Approved for Market in Japan
Time of Update: 2021-09-06
This approval is based on the results of the global Phase 3 clinical trial REGN-COV 2067 for high-risk non-hospitalized patients with COVID-19.
-
WuXi Giant Nuo BCMA Targeted CAR-T Therapy Applied for Clinical Application
Time of Update: 2021-09-06
Today, the Center for Drug Evaluation (CDE) of the National Medical Products Administration of China announced that WuXi Junuo's JWCAR129 (targeting BCMA chimeric antigen receptor T cell) clinical trial application has been accepted .
Screenshot source: CDE official website
-
Single-dose adenovirus vaccines against multiple new coronavirus mutations such as Delta show neutralizing activity
Time of Update: 2021-09-06
In the preprint study submitted by Johnson & Johnson, the researchers evaluated the neutralizing ability of the serum of eight volunteers who participated in the phase 3 clinical trial .
-
Progress in cGAS inhibitor research
Time of Update: 2021-09-06
The new compounds were tested for their inhibitory activity against the cGAS signaling pathway stimulated by dsDNA in human THP1-Dual cells and murine RAW-Lucia ISG cells.
Mechanism studies have found that the new compound has a direct targeting effect on cGAS in THP1-Dual cells .
-
Open medical electronic bronchoscope and obtain medical device registration certificate
Time of Update: 2021-09-06
On July 20, Kaili Medical issued an announcement stating that the company’s electronic bronchoscope has been approved by the Guangdong Provincial Drug Administration, and recently obtained the People’s Republic of China Medical Device Registration Certificate .
-
Social skills are also related to the intestines?
Time of Update: 2021-09-06
Recently, researchers published a research paper in the top academic journal "Nature", revealing how intestinal bacteria affect the activity of the brain's neural network, leading to changes in the social behavior of mice .
-
The latest neutralization efficacy results of mRNA vaccines against more than ten mutant virus strains such as Delta are released
Time of Update: 2021-09-06
Today, Moderna announced its mRNA new coronavirus vaccine, the results of the neutralization ability of a variety of new coronavirus mutant strains including Delta .
1 times, for the Gamma virus strain, the serum neutralization titer was reduced by 3.
-
"Functional Cure" Hepatitis B Dawn, Neutralizing Antibody and RNAi Therapy, The Newest Clinical Results Are Positive
Time of Update: 2021-09-06
▲VIR-2218 combined with PEG-IFN-α to further reduce the level of HBsAg (picture source: reference [4])Vir is currently or planned clinical trials, the VIR-2218 with different types of immunomodulatory drug combination, and explore the potential of combination therapy to cure hepatitis B in terms of functionality .
-
NEJM: 40% low viral load, mild symptoms and quick recovery, the new crown vaccine reduces the impact of infection
Time of Update: 2021-09-06
Although it is difficult to prevent infection 100%, the new crown vaccine helps to reduce the symptoms of new crown virus disease (COVID-19), which has been tested in clinical trials, but there are not many real-world data on this .
-
Metformin discovers new effects
Time of Update: 2021-09-06
The article pointed out that recently Nikolaj Rittig, a clinical research expert at the Steinau Diabetes Center of Aarhus University Hospital in Denmark, and his team published a latest clinical research result in the journal AP&T:Metformin can significantly reduce the hepatic venous pressure gradient (HVPG) in patients with portal hypertension caused by liver cirrhosis .
-
Inflammation in early life may induce depression in adolescence
Time of Update: 2021-09-06
New knowledgeOn July 7th, the reporter learned from the University of Science and Technology of China that a joint study by Zhang Zhi, Jin Yan’s research team and the Xu Lin team of the Chinese Academy of Sciences found that inflammation in the early stages of life leads to the development of an individual’s anterior cingulate cortex (ACC) during puberty.
-
Specialized immune cells ensure the balance and efficient operation of the brain. There is a group of "operators" in the brain.
Time of Update: 2021-09-06
According to a report in "Cell" on the 6th, a new study jointly conducted by scientists from Harvard Medical School and the Broad Institute in the United States showed for the first time that the delicate balance between inhibition and excitement in the brain is composed of highly specialized small glues.
-
Frontier "The Lancet" publishes "mixed inoculation" test results
Time of Update: 2021-09-06
The results showed that in the intervention group, the antibody level increased significantly after the second injection of mixed vaccination .
-
Bristol-Myers Squibb LAG-3/PD-1 combination therapy is clinically approved in China
Time of Update: 2021-09-06
Previously, its combination therapy with the anti-PD-1 antibody nivolumab (Opdivo, nivolumab) has been used to treat 2/3 of newly-treated patients with metastatic or unresectable melanoma In phase 3 clinical trials, the primary endpoint of progression-free survival (PFS) was reached.
This is also the world's first phase 3 clinical trial to report the efficacy of anti-LAG-3 antibodies .
-
Chinese experts find that the delivery mechanism provides a new strategy for the prevention and treatment of premature birth
Time of Update: 2021-09-06
The reporter learned on the 5th that the team of Professor Sun Gang from the Reproductive Medicine Center of Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine and Shanghai Key Laboratory of Assisted Reproduction and Eugenics was the first to discover that the transcription enhancer binding protein (CEBPδ) may be involved in the activation of fetal membranes and the initiation of labor.
-
The latest study from the University of Cambridge: "Spinal Cord Stimulation" helps you get rid of stubborn pain, thin as hair, without invasive surgery
Time of Update: 2021-09-06
Very limited and ineffective; the paddle electrodes, which are usually as wide as 12 mm, are effective in relieving pain, but the main disadvantage is that they require invasive and higher-risk surgical procedures to implant the device .
